

## Supriya Lifescience invests Rs 120 Cr in new API production block

17 December 2024 | News

### Facility houses 33 reactors, comprising stainless steel and glass-lined varieties



Supriya Lifescience Limited (SLL), a leader in the pharmaceutical industry, has taken another significant step on its ambitious growth trajectory with the inauguration of its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site, in Maharashtra.

The facility, developed with an investment of approximately Rs 120 crore, adds a substantial capacity of 335 kiloliters to the company's operations. This expansion boosts the Lote Parshuram capacity by over 55%, increasing it from 597 KLPD (kilo liters per day) to 932 KLPD.

The new production block is designed to support SLL's strategic focus on expanding its R&D capabilities and scaling up its pipeline of innovative products. Several new products in niche therapeutic areas are nearing the commercialisation stage, reinforcing SLL's commitment to achieving a leadership position in these markets through efficient processes and backward integration.

The facility is tailored to support the company's backward integration model, ensuring economies of scale and a competitive edge. It is spread across 5,000 square meters and structured over four levels, the facility enables efficient operations and safe workflows. The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL.

The design leverages gravity-based process flows to enhance safety, maintain product integrity, and optimize efficiency.

Incorporating closed-system handling at critical stages, the facility is equipped with process control automation systems and material handling systems to ensure compliance with the latest quality standards. The facility is equipped to handle a variety of unit processes and operations, making it adaptable to future needs.